The Rapid AML Therapeutic Panel was designed to assess key biomarkers associated with acute myeloid leukemia (AML) through a combination of next-generation sequencing (NGS) and FISH. Test reports include a summary of all results to help guide treatment decisions.
Rapid AML Therapeutic Panel
- Molecular
Specimen Requirements
Bone Marrow Aspirate: 2-3 mL in sodium heparin tube. EDTA is acceptable.
Peripheral Blood: 5 mL in sodium heparin tube. EDTA is acceptable.
Fluids: Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.
CPT Code(s)*
Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive Myeloid Disorders, or one of the NeoTYPE Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.
Turnaround time
10 Days
FISH: 5 Days
FLT3, IDH1, IDH2: 5 Days
CEBPA, NPM1, TP53: 7-10 Days
Level of Service
- Global
Integrations
Request electronic integrations →
New York Approved: No
Clinical Significance
The Rapid AML Therapeutic Panel identifies genetic abnormalities associated with Acute Myeloid Leukemia (AML) that are useful for risk stratification and therapeutic decision making. This panel utilizes a combination of bi-directional Sanger sequencing, PCR and FISH with a fast turnaround time. AML is usually an in-patient hematologic diagnosis and prompt time to treatment assignment can improve patient outcomes significantly.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Biomarkers
DNA Sequencing
| SNVs + Indels | |||||
|---|---|---|---|---|---|
| CEBPA | FLT3 | IDH1 | IDH2 | NPM1 | TP53 |
Fluorescence In Situ Hybridization (FISH)
| Translocation(s) | |||||
|---|---|---|---|---|---|
| PML/RARA t(15;17) | RUNX1T1/RUNX1 (ETO/AML1) t(8;21) | ||||
| Deletion(s) | |||||
|---|---|---|---|---|---|
| 17p- | 5q- | 7q- | |||
| Rearrangement(s) | |||||
|---|---|---|---|---|---|
| MLL | |||||
| Inversion(s) | |||||
|---|---|---|---|---|---|
| CBFB inv(16), t(16;16) | |||||
Last Updated: June 17, 2026